Covered recipient · General Payments record
PERRY SHIEH
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$347,742.64
470 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $107,666.45 | 22 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $93,790.00 | 28 |
| Travel and Lodging | $75,247.10 | 159 |
| Honoraria | $40,379.90 | 14 |
| Education | $20,103.89 | 81 |
| Food and Beverage | $10,555.30 | 166 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Biogen, Inc. | $115,273.64 | 157 |
| Sarepta Therapeutics, Inc. | $82,593.82 | 59 |
| AveXis | $65,027.16 | 123 |
| Alexion Pharmaceuticals, Inc. | $25,541.41 | 41 |
| Genentech USA, Inc. | $24,418.36 | 20 |
| Grifols USA, LLC | $12,845.73 | 20 |
| CSL Behring | $6,208.43 | 13 |
| CATALYST PHARMACEUTICALS, INC. | $5,635.43 | 9 |
| Genentech, Inc. | $5,439.86 | 7 |
| PTC Therapeutics, Inc. | $2,770.07 | 12 |
| PFIZER INC. | $1,988.73 | 9 |
Page 10 of 10; records 451–470 of 470 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PERRY SHIEH
NPI 1588683395 · CMS profile ID 253101
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
LOS ANGELES, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 10 of 10; records 451–470 of 470 matching records. This page contains 20 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1588683395?year=2019&recipient=provider&page=10#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PERRY SHIEH, NPI 1588683395, CMS profile ID 253101. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 10 of 10; records 451–470 of 470 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588683395?year=2019&recipient=provider&page=10#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). PERRY SHIEH, NPI 1588683395, CMS profile ID 253101. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 10 of 10; records 451–470 of 470 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588683395?year=2019&recipient=provider&page=10#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- PERRY SHIEH, NPI 1588683395, CMS profile ID 253101, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 10 of 10; records 451–470 of 470 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1588683395?year=2019&recipient=provider&page=10#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
470 matching records · $347,742.64 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 451–470 of 470.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $320.18 | 01/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673816613 | CMS |
| PFIZER INC. | $346.20 | 01/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673821797 | CMS |
| Sarepta Therapeutics, Inc. | $114.95 | 01/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681676075 | CMS |
| Sarepta Therapeutics, Inc. | $17.91 | 01/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681676093 | CMS |
| Sarepta Therapeutics, Inc. | $8,843.29 | 01/24/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681676167 | CMS |
| CSL Behring | $1,200.00 | 01/21/2019 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 683839975 | CMS |
| PFIZER INC. | $65.47 | 01/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673805359 | CMS |
| Biogen, Inc. | $14.10 | 01/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660651997 | CMS |
| Alexion Pharmaceuticals, Inc. | $18.40 | 01/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695538143 | CMS |
| CSL Behring | $450.00 | 01/10/2019 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 683839973 | CMS |
| PTC Therapeutics, Inc. | $735.91 | 01/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701219739 | CMS |
| PTC Therapeutics, Inc. | $1,250.00 | 01/09/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701219741 | CMS |
| PTC Therapeutics, Inc. | $34.99 | 01/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701219743 | CMS |
| PTC Therapeutics, Inc. | $28.92 | 01/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701219745 | CMS |
| PTC Therapeutics, Inc. | $16.70 | 01/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701219747 | CMS |
| PTC Therapeutics, Inc. | $6.42 | 01/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701219749 | CMS |
| PTC Therapeutics, Inc. | $34.84 | 01/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701219751 | CMS |
| PTC Therapeutics, Inc. | $30.30 | 01/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701219753 | CMS |
| PTC Therapeutics, Inc. | $234.66 | 01/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701219755 | CMS |
| PTC Therapeutics, Inc. | $330.00 | 01/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701219757 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $5,004.62 | 3 |
| PY2025 | Principal investigator | $611,343.64 | 106 |
| PY2024 | Recipient | $15,612.73 | 9 |
| PY2024 | Principal investigator | $1,500,264.79 | 94 |
| PY2023 | Recipient | $10,346.12 | 18 |
| PY2023 | Principal investigator | $916,305.22 | 134 |
| PY2022 | Recipient | $7,010.00 | 7 |
| PY2022 | Principal investigator | $329,507.55 | 88 |
| PY2021 | Recipient | $818.28 | 3 |
| PY2021 | Principal investigator | $731,667.65 | 75 |
| PY2020 | Principal investigator | $968,806.04 | 72 |
| PY2019 | Principal investigator | $657,183.90 | 74 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
109 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $4,851.00 | 12/24/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | LONGTERM FOLLOWUP SAFETY AND EFFICACY STUDY IN PARTICIPANTS WITH DUCHENNE MUSCULAR DYSTROPHY WHO HAVE RECEIVED FORDADISTROGENE MOVAPARVOVEC IN A PRECEDING CLINICAL STUDY | No dispute reported | 06/30/2026 | 1228816193 |
| Principal investigator 1 | PFIZER INC. | $6,935.87 | 12/15/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1228805875 |
| Principal investigator 1 | PFIZER INC. | $6,989.72 | 12/15/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1228805880 |
| Principal investigator 1 | PFIZER INC. | $6,935.87 | 12/15/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1228805965 |
| Principal investigator 1 | PFIZER INC. | $6,130.14 | 12/15/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1228805970 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 12/10/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) | No dispute reported | 06/30/2026 | 1215521958 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,629.61 | 12/05/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223611669 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $3,908.42 | 12/05/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223611671 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $3,908.42 | 12/05/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613478 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,629.61 | 12/05/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613480 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $3,908.42 | 12/05/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613482 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $3,908.42 | 12/05/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613484 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $2,205.00 | 11/25/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249092781 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $1,275.75 | 11/25/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249092783 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $19,404.00 | 11/25/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249092785 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $2,520.00 | 11/25/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249092787 |
| Principal investigator 1 | PFIZER INC. | $15,813.56 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1228821228 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,560.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223611629 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,260.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223611631 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,260.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223611633 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,560.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223611635 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,560.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223611637 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,560.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223611639 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $780.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223611641 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,560.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223611643 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,260.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223611645 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,260.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223611647 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,560.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223611649 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,560.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223614381 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,560.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223614383 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,560.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223614385 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,560.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223614387 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,560.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223614389 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,260.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223614391 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,560.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223614393 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,560.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223614395 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $630.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223614397 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,560.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223614399 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,260.00 | 11/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223614401 |
| Principal investigator 1 | PFIZER INC. | $14,300.04 | 11/07/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF 06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1228820684 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $14.40 | 11/04/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223616096 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $120.68 | 11/04/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223616098 |
| Principal investigator 1 | PFIZER INC. | $4,869.90 | 11/01/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | LONGTERM FOLLOWUP SAFETY AND EFFICACY STUDY IN PARTICIPANTS WITH DUCHENNE MUSCULAR DYSTROPHY WHO HAVE RECEIVED FORDADISTROGENE MOVAPARVOVEC IN A PRECEDING CLINICAL STUDY | No dispute reported | 06/30/2026 | 1228819332 |
| Principal investigator 1 | PFIZER INC. | $6,935.87 | 10/30/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1228814134 |
| Principal investigator 1 | PFIZER INC. | $5,658.51 | 10/30/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1228814139 |
| Principal investigator 1 | PFIZER INC. | $495.16 | 10/30/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1228814152 |
| Principal investigator 1 | PFIZER INC. | $5,903.10 | 10/25/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | LONGTERM FOLLOWUP SAFETY AND EFFICACY STUDY IN PARTICIPANTS WITH DUCHENNE MUSCULAR DYSTROPHY WHO HAVE RECEIVED FORDADISTROGENE MOVAPARVOVEC IN A PRECEDING CLINICAL STUDY | No dispute reported | 06/30/2026 | 1228825924 |
| Principal investigator 1 | PFIZER INC. | $15,813.56 | 10/02/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1228814125 |
| Principal investigator 1 | PFIZER INC. | $5,197.50 | 09/29/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1228821204 |
| Principal investigator 1 | PFIZER INC. | $4,662.00 | 09/10/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1228821211 |
| Principal investigator 1 | PFIZER INC. | $1,386.00 | 09/10/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1228821216 |
| Principal investigator 1 | PFIZER INC. | $4,158.00 | 09/10/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1228821222 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $640.71 | 08/29/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249092773 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $9,664.00 | 07/18/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Phase 3, Randomized, Double blind, Placebo controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1185547163 |
| Recipient | PFIZER INC. | $780.00 | 07/10/2025 | Covered Recipient Physician | PF06755347 CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228802374 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $58.88 | 07/09/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223612421 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $8.10 | 06/30/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613021 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1.20 | 06/30/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613023 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.88 | 06/30/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613025 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.92 | 06/30/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613027 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.68 | 06/30/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613029 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1.44 | 06/30/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613031 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $2.06 | 06/30/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613033 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $32.54 | 06/30/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613035 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.56 | 06/30/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613037 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $8.70 | 06/30/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613039 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $0.12 | 06/30/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613041 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $13.89 | 06/30/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613043 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1.66 | 06/30/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613045 |
| Principal investigator 1 | PFIZER INC. | $26,004.83 | 06/04/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A PHASE 1B MULTICENTER OPENLABEL SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF06939926 IN AMBULATORY AND NONAMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY | No dispute reported | 06/30/2026 | 1228844304 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $3,276.00 | 05/19/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249092767 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $711.90 | 05/15/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223615659 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $1,275.75 | 04/30/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249092763 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $3,908.42 | 04/30/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223613875 |
| Recipient | Novartis Pharmaceuticals Corporation | $3,876.87 | 04/25/2025 | Covered Recipient Physician | RESTORE | No dispute reported | 06/30/2026 | 1190293203 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $2,079.00 | 04/17/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223613877 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $10,962.00 | 04/17/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223613879 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,260.00 | 04/17/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223613881 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $2,520.00 | 04/17/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223613883 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $55.44 | 04/17/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223613885 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $7,812.00 | 04/17/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223613887 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $3,150.00 | 04/17/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223613889 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,890.00 | 04/17/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223613891 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $693.00 | 04/17/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223613893 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $207.90 | 04/17/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-301 | No dispute reported | 06/30/2026 | 1223613895 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,248.00 | 04/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) | No dispute reported | 06/30/2026 | 1215516809 |
| Principal investigator 1 | Biogen, Inc. | $9,072.00 | 04/02/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy | No dispute reported | 06/30/2026 | 1236947022 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,092.18 | 03/25/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 4045-301 | No dispute reported | 06/30/2026 | 1223614467 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $10,818.38 | 03/18/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 4045-301 | No dispute reported | 06/30/2026 | 1223614465 |
| Recipient | Novartis Pharma AG | $347.75 | 03/15/2025 | Covered Recipient Physician | COAV101A12001 | No dispute reported | 06/30/2026 | 1248109805 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $12,164.04 | 03/11/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 4045-301 | No dispute reported | 06/30/2026 | 1223614463 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $909.72 | 03/11/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 4045-301 | No dispute reported | 06/30/2026 | 1223614475 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $10,424.13 | 03/11/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 4045-301 | No dispute reported | 06/30/2026 | 1223614477 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $63,678.79 | 03/11/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 4045-301 | No dispute reported | 06/30/2026 | 1223614479 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $31,839.39 | 03/11/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 4045-301 | No dispute reported | 06/30/2026 | 1223614481 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $136,570.14 | 03/04/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 4045-301 | No dispute reported | 06/30/2026 | 1223614461 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $640.71 | 02/27/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | No dispute reported | 06/30/2026 | 1249092759 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $130.92 | 02/18/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223615450 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $2,322.21 | 01/29/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223615446 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $1,629.61 | 01/29/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | SRP-9001-305 | No dispute reported | 06/30/2026 | 1223615448 |
| Principal investigator 1 | UCB SA | $7,833.40 | 01/27/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A PHASE 3B, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF ZILUCOPLAN IN PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS SWITCHING FROM INTRAVENOUS COMPLEMENT COMPONENT 5 INHIBITORS TO SUBCUTANEOUS ZILUCOPLAN | No dispute reported | 06/30/2026 | 1246659539 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $6,120.33 | 01/23/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 4045-301 | No dispute reported | 06/30/2026 | 1223614457 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $17,125.25 | 01/23/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 4045-301 | No dispute reported | 06/30/2026 | 1223614459 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $11,645.73 | 01/23/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 4045-301 | No dispute reported | 06/30/2026 | 1223614469 |
| Principal investigator 1 | Biogen, Inc. | $8,568.00 | 01/16/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | An Open-Label Extension Study for Patients With Spinal Muscular AtrophyWho Previously Participated in Investigational Studies of ISIS 396443 | No dispute reported | 06/30/2026 | 1236947632 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $642.60 | 01/16/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 4045-301 | No dispute reported | 06/30/2026 | 1223614471 |
| Principal investigator 1 | Sarepta Therapeutics, Inc. | $4,536.00 | 01/16/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 4045-301 | No dispute reported | 06/30/2026 | 1223614473 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $851.00 | 01/15/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) | No dispute reported | 06/30/2026 | 1215516803 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $2,460.00 | 01/01/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Phase 1/2, Randomized, Double-blind, Placebo?controlled Single- and Multiple?dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX?670 in Adult Subjects with Myotonic Dystrophy Type 1 | No dispute reported | 06/30/2026 | 1214124058 |